Stryker Q1 Earnings: Procedure Demand, Margins, and Expectations

Wall Street is watching SYK's first-quarter 2026 earnings with close attention to two metrics: procedure demand in hospital systems and margin performance against rising input costs. Analyst consensus calls for Q1 EPS of $2.98 per share — up 4.9% year-over-year — on revenues of $6.29 billion, representing 7.3% growth.

Stryker enters the report with momentum: four consecutive earnings beats and Q4 2025 revenues of $7.17 billion, up 11.4% year-over-year. The MedSurg and Neurotechnology segment — expected to deliver $3.92 billion in Q1 revenue — is a key bellwether for hospital capital spending and elective procedure scheduling, both of which have shown resilience despite macro uncertainty.

Among 28 analysts covering SYK, 18 rate it a strong buy with a mean price target of $422.30, implying approximately 24% upside. The primary risk is whether tariff-driven supply chain costs and China manufacturing exposure compress gross margins in medical device production — an industry-wide concern as input cost pressures remain elevated through 2026.

Related Stocks

• SYK